Literature DB >> 16863448

Pharmacodynamics of antimicrobials: treatment optimisation.

Effie L Gillespie1, Joseph L Kuti, David P Nicolau.   

Abstract

As bacterial resistance continues to increase, optimising the potential for successful clinical outcomes with antimicrobial therapy requires consideration of pharmacodynamic concepts in order to maximise bacterial eradication and minimise the potential for further resistance. Based on the pharmacodynamic characteristics of specific antibiotics, dosage modifications can be implemented to improve the likelihood of bactericidal exposure. Considering their concentration-dependent bactericidal activity, aminoglycosides benefit from increased dosages and infrequent administration, so as to achieve a maximum concentration/minimum inhibitory concentration (MIC) of 10-12. In contrast, beta-lactams are concentration-independent killers and benefit greatest by increasing the time above the MIC (T > MIC). This can be accomplished with the use of prolonged or continuous infusion. By optimising pharmacodynamic parameters with these methodologies, successful treatment of pathogens may be possible in patient populations for whom standard dosing regimens are not effective.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16863448     DOI: 10.1517/17425255.1.3.351

Source DB:  PubMed          Journal:  Expert Opin Drug Metab Toxicol        ISSN: 1742-5255            Impact factor:   4.481


  9 in total

1.  The relative contributions of physical structure and cell density to the antibiotic susceptibility of bacteria in biofilms.

Authors:  Amy E Kirby; Kimberly Garner; Bruce R Levin
Journal:  Antimicrob Agents Chemother       Date:  2012-03-26       Impact factor: 5.191

2.  Population dynamics of antibiotic treatment: a mathematical model and hypotheses for time-kill and continuous-culture experiments.

Authors:  Bruce R Levin; Klas I Udekwu
Journal:  Antimicrob Agents Chemother       Date:  2010-06-01       Impact factor: 5.191

3.  Pharmacodynamic target attainment for various ceftazidime dosing schemes in high-flux hemodialysis.

Authors:  Angela S Loo; Michael Neely; Evan J Anderson; Cybele Ghossein; Milena M McLaughlin; Marc H Scheetz
Journal:  Antimicrob Agents Chemother       Date:  2013-09-09       Impact factor: 5.191

4.  Antibiotic administration in the drinking water of mice.

Authors:  James O Marx; Daljit Vudathala; Lisa Murphy; Shelley Rankin; F Claire Hankenson
Journal:  J Am Assoc Lab Anim Sci       Date:  2014-05       Impact factor: 1.232

5.  Cefepime dosing in the morbidly obese patient population.

Authors:  Barrie S Rich; Rebecca Keel; Vanessa P Ho; Harma Turbendian; Cheguevara I Afaneh; Gregory F Dakin; Alfons Pomp; David P Nicolau; Philip S Barie
Journal:  Obes Surg       Date:  2012-03       Impact factor: 4.129

6.  Application of the Hartford Hospital Nomogram for Plazomicin Dosing Interval Selection in Patients with Complicated Urinary Tract Infection.

Authors:  Tomefa E Asempa; Joseph L Kuti; Julie D Seroogy; Allison S Komirenko; David P Nicolau
Journal:  Antimicrob Agents Chemother       Date:  2019-09-23       Impact factor: 5.191

7.  Stability of Amoxicillin and Clavulanic Acid in Separate Containers for Administration via a Y-Site.

Authors:  Sarah Fawaz; Mahboub Merzouk; Stephen Barton; Shereen Nabhani-Gebara
Journal:  Drug Des Devel Ther       Date:  2021-09-21       Impact factor: 4.162

8.  Staphylococcus aureus in continuous culture: a tool for the rational design of antibiotic treatment protocols.

Authors:  Klas I Udekwu; Bruce R Levin
Journal:  PLoS One       Date:  2012-07-20       Impact factor: 3.240

9.  A pharmacodynamic analysis of resistance trends in pathogens from patients with infection in intensive care units in the United States between 1993 and 2004.

Authors:  Kathryn J Eagye; David P Nicolau; Shawn R Lockhart; John P Quinn; Gary V Doern; Gale Gallagher; Murray A Abramson
Journal:  Ann Clin Microbiol Antimicrob       Date:  2007-10-01       Impact factor: 3.944

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.